- Home
- AKAN vs CMND Comparison
AKAN vs CMND Comparison
Compare AKAN & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKAN | CMND |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AKAN | CMND |
|---|---|---|
| Price | $0.64 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 123.6K | 99.2K |
| Earning Date | 04-29-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.07 |
| 52 Week High | $9.29 | $3.25 |
Technical Indicators
Market Signals| Indicator | AKAN | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 60.63 |
| Support Level | $0.51 | $0.99 |
| Resistance Level | $1.12 | $1.27 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 32.73 | 79.84 |
Price Performance
Historical ComparisonAbout AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.